Posted by Michael Wonder on 13 Jan 2022
The US FDA issues a complete response letter for the biologics license application for insulin aspart
7 January 2022 - The U.S. FDA has issued a complete response letter for the biologics license application for insulin aspart filed by Viatris (Mylan).
The complete response letter did not identify any outstanding scientific issues with the product.
